CytoSorbents Corporation

8.90+0.0200+0.23%Vol 107.79K1Y Perf 34.90%
Apr 9th, 2021 16:00 DELAYED
BID8.89 ASK8.91
Open8.82 Previous Close8.88
Pre-Market- After-Market8.90
 - -  - -%
Target Price
14.75 
Analyst Rating
Strong Buy 1.00
Potential %
65.73 
Finscreener Ranking
★★★★★     59.91
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★+     49.97
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★★     62.85
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap385.05M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
38.39 
Earnings Date
4th May 2021

Today's Price Range

8.678.94

52W Range

7.1311.74

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
1.14%
1 Month
3.61%
3 Months
-0.22%
6 Months
8.27%
1 Year
34.90%
3 Years
17.11%
5 Years
117.07%
10 Years
-

TickerPriceChg.Chg.%
CTSO8.900.02000.23
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Financial StrengthValueIndustryS&P 500US Markets
7.50
8.10
0.01
0.01
-6.50
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
72.00
-30.30
-28.50
-74.30
-12.79
RevenueValueIndustryS&P 500US Markets
32.30M
0.75
31.67
44.96
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.020.00100.00
Q03 2020-0.09-0.0277.78
Q02 2020-0.08-0.080.00
Q01 2020-0.14-0.1028.57
Q04 2019-0.17-0.1323.53
Q03 2019-0.14-0.21-50.00
Q02 2019-0.14-0.1121.43
Q01 2019-0.18-0.1516.67
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.03-200.00Negative
6/2021 QR-0.04-500.00Negative
12/2021 FY-0.13-44.44Negative
12/2022 FY0.07-50.00Negative
Next Report Date4th May 2021
Estimated EPS Next Report-0.03
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume107.79K
Shares Outstanding43.26M
Trades Count1.34K
Dollar Volume2.99M
Avg. Volume347.33K
Avg. Weekly Volume142.23K
Avg. Monthly Volume268.39K
Avg. Quarterly Volume348.21K

CytoSorbents Corporation (NASDAQ: CTSO) stock closed at 8.9 per share at the end of the most recent trading day (a 0.23% change compared to the prior day closing price) with a volume of 107.81K shares and market capitalization of 385.05M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 156 people. CytoSorbents Corporation CEO is Phillip P. Chan.

The one-year performance of CytoSorbents Corporation stock is 34.9%, while year-to-date (YTD) performance is 11.67%. CTSO stock has a five-year performance of 117.07%. Its 52-week range is between 7.13 and 11.74, which gives CTSO stock a 52-week price range ratio of 38.39%

CytoSorbents Corporation currently has a PE ratio of -, a price-to-book (PB) ratio of 63.48, a price-to-sale (PS) ratio of 11.76, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -13.09%, a ROC of -16.84% and a ROE of -18.90%. The company’s profit margin is -12.79%, its EBITDA margin is -28.50%, and its revenue ttm is $32.30 Million , which makes it $0.75 revenue per share.

Of the last four earnings reports from CytoSorbents Corporation, there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.03 for the next earnings report. CytoSorbents Corporation’s next earnings report date is 04th May 2021.

The consensus rating of Wall Street analysts for CytoSorbents Corporation is Strong Buy (1), with a target price of $14.75, which is +65.73% compared to the current price. The earnings rating for CytoSorbents Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CytoSorbents Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CytoSorbents Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 23.68, ATR14 : 0.60, CCI20 : -101.80, Chaikin Money Flow : -0.09, MACD : -0.41, Money Flow Index : 31.16, ROC : -16.59, RSI : 36.08, STOCH (14,3) : 27.93, STOCH RSI : 0.75, UO : 43.82, Williams %R : -72.07), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CytoSorbents Corporation in the last 12-months were: Al W. Kraus (Option Excercise at a value of $27 600), Al W. Kraus (Sold 8 000 shares of value $64 000 ), Edward R. Jones (Option Excercise at a value of $26 800), Kathleen P. Bloch (Option Excercise at a value of $56 000), Phillip P. Chan (Option Excercise at a value of $264 798), Vincent Capponi (Option Excercise at a value of $244 978), Vincent Capponi (Sold 20 000 shares of value $200 000 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
4 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

CytoSorbents Corporation

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries.The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.

CEO: Phillip P. Chan

Telephone: +1 732 329-8885

Address: 7 Deer Park Drive, Monmouth Junction 08852, NJ, US

Number of employees: 156

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

57%43%

Bearish Bullish

59%41%

News

Stocktwits